Science For The Real World: Canadian Hematology Today

Science for the Real World is designed to illuminate hot topics in Canadian healthcare through a series of conversations with Canadian clinicians. Canadian Hematology Today presents robust clinical perspectives and practical insights on the treatment and management of hematologic diseases.<hr /><p style="color: grey; font-size: 0.75em;"> Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer" style="color: grey;" target="_blank">acast.com/privacy</a> for more information.</p>

Prise en charge des patients atteints de LLC doublement exposée et réfractaire.

Hosted on Acast. See acast.com/privacy for more information.

11-18
16:48

Addressing the management of patients with double exposed and refractory CLL

Sponsored by Eli Lilly Hosted on Acast. See acast.com/privacy for more information.

11-18
17:40

CAR T-cell Therapy in 2025: Evidence, Safety, and Patient Selection

Sponsored by Bristol Myers Squibb. Hosted on Acast. See acast.com/privacy for more information.

09-24
24:35

Practical considerations in the management of early rrMM in the Canadian context

This podcast features Dr. Christopher Venner and his colleagues from the hematology community, Dr. Sylvia McCulloch, Dr. Arleigh McCurdy, and Dr. Chai Phua discussing the approach to the management of early rrMM in the Canadian context.This episode of Science for the Real World is part of Canadian Hematology Today, an open-access scientific journal for the hematology community. Hosted on Acast. See acast.com/privacy for more information.

01-06
32:00

The role of selinexor in early rrMM and sequencing in 2024.

In this episode of "Science for the Real World: Canadian Hematology Today," Dr. Peter Anglin hosts a discussion with Dr. Joshua Richter and Dr. Darrell White on the management of early rrMM in 2024, focusing on the role of selinexor and treatment sequencing. Hosted on Acast. See acast.com/privacy for more information.

06-26
27:34

Recommend Channels